International Markets and Bio-Rad (BIO): A Deep Dive for Investors

Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Zacks Investment Research • Feb 20, 2026

Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down

BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.

Zacks Investment Research • Feb 19, 2026

Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 13, 2026

Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and.

Business Wire • Feb 12, 2026

Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago.

Zacks Investment Research • Feb 12, 2026

Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-196.

Business Wire • Jan 29, 2026

Here's Why You Should Hold Bio-Rad Stock in Your Portfolio Now

BIO benefits from steady Clinical Diagnostics demand and international growth, but macro pressures and currency headwinds could cap near-term upside.

Zacks Investment Research • Jan 21, 2026

Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity

Online travel agency Expedia, our top overall contributor in Q4, drove performance in the consumer discretionary sector. Our top performers in the energy and financials sectors were NOV, a provider of oilfield equipment, technology and expertise, and First Citizens, a North Carolina-based bank. Our largest new purchase was Houston-headquartered Prosperity BancShares, the fifth-largest bank in Texas.

Seeking Alpha • Jan 21, 2026

Longleaf Partners Global Fund 2025 Contributors And Detractors

French pay-TV operator Canal+ was a contributor for the year. After a tough start in 2025, momentum in Glanbia's core Performance Nutrition business improved from low single-digit growth rates. Millicom extended its strong 2024 performance through 2025, with the share price tracking operational delivery and the visible inflection in equity FCF we flagged in prior letters.

Seeking Alpha • Jan 15, 2026

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, Chief Operating Officer Jon DiVincenzo, and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during J.P. Morgan's 44th Annual Healthcare Conference in San Francisco, CA, January 12-15, 2026. About Bio-Rad Bio-Ra.

Business Wire • Jan 6, 2026